呼吸道合胞病毒，一个持续存在的医学难题：关于目前正在进行临床试验的呼吸道合胞病毒预防和治疗药物的专家评论
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.
作者信息
Broadbent Lindsay, Groves Helen, Shields Michael D, Power Ultan F
机构信息
Centre for Infection & Immunity, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, Belfast, UK.
The Royal Belfast Hospital for Sick Children, Belfast, UK.
出版信息
Influenza Other Respir Viruses. 2015 Jul;9(4):169-78. doi: 10.1111/irv.12313.
As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.
作为婴儿严重呼吸道疾病的最重要病毒病因，并且在老年人和免疫功能低下者中也日益被视为重要病因，呼吸道合胞病毒（RSV）在全球造成了巨大的健康负担。针对RSV的预防性抗体已成功研发出来。然而，它们的使用仅限于一小部分被认为有患严重RSV疾病高风险的婴儿。目前仍没有对抗RSV的特异性治疗方法或疫苗。因此，对大多数人来说，这仍然是一项未得到满足的主要医疗需求。世界卫生组织国际临床试验注册平台（WHO ICTRP）和PubMed被用于识别和审查目前正在进行临床试验的所有RSV疫苗、预防药物和治疗药物候选物。本综述对自2008年以来进入临床试验的所有RSV特异性预防和治疗候选物进行了专家评论。
Zotero 插件